May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Efficacy of the MicroBlockTM Antimicrobial Lens Case Against Clinical Isolates and ATCC Solution Challenge Panel Strains
Author Affiliations & Notes
  • M. George
    Lens Care Development, CIBA Vision Corporation, Duluth, GA
  • M. Ajello
    Lens Care Development, CIBA Vision Corporation, Duluth, GA
  • S. Lambert
    Lens Care Development, CIBA Vision Corporation, Duluth, GA
  • M. Mowrey–Mckee
    Lens Care Development, CIBA Vision Corporation, Duluth, GA
  • C. Amos
    Lens Care Development, CIBA Vision Corporation, Duluth, GA
  • Footnotes
    Commercial Relationships  M. George, CIBA Vision Corporation E; M. Ajello, CIBA Vision Corporation E; S. Lambert, CIBA Vision Corporation E; M. Mowrey–Mckee, CIBA Vision Corporation E; C. Amos, CIBA Vision Corporation E.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1561. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. George, M. Ajello, S. Lambert, M. Mowrey–Mckee, C. Amos; Efficacy of the MicroBlockTM Antimicrobial Lens Case Against Clinical Isolates and ATCC Solution Challenge Panel Strains . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1561.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:Microbial contamination of lens cases may occur despite the effectiveness of currently marketed contact lens disinfection systems. Microorganisms isolated from contact–lens–associated corneal ulcers are often identical to those isolated from the patient’s associated lens case. A number of patients with contaminated lens cases also report having problems wearing their contact lenses, such as eye dryness, itching, and redness. In an attempt to reduce the degree of contamination of lens cases, the MicroBlockTM antimicrobial lens case was developed. Efficacy of the MicroBlockTM case against clinical isolates and ATCC solution challenge panel isolates was assessed. Performance of the MicroBlockTM case versus standard market lens cases also was examined. Methods:Bowls of MicroBlockTM and competitor lens cases were directly challenged with 103 CFU/mL suspensions of clinical isolates, including one from a microbial keratitis patient, and ATCC solution challenge panel isolates of bacteria and yeast in phosphate buffered saline. This challenge level was chosen to more closely mimic real world lens case contamination levels. Sample efficacy was assessed after 24 hrs incubation. Results:The MicroBlockTM case demonstrated significant bactericidal efficacy against clinical and ATCC isolates. The MicroBlockTM case’s performance was superior to all competitor cases evaluated for each strain tested, including those cases with some inherent antimicrobial activity. Conclusions:The MicroBlockTM case is efficacious against clinical isolates and solution challenge panel strains. It is a promising device for reducing the incidence of microbial lens case contamination.

Keywords: contact lens • microbial pathogenesis: experimental studies • antibiotics/antifungals/antiparasitics 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×